< Back to Press Releases
Global Biopharmaceutical Company Addresses the Industry's Rapid Transformation Towards Emerging Markets and Technologies
WATERTOWN, MA – (BUSINESS WIRE) – August 18, 2010 – Wolfe Laboratories, Inc. (WLI) will host the 2010 Wolfe Biopharma Conference, Emerging Markets and Technologies: 2020 VisionTM, on Tuesday, October 19, 2010 at The Ritz-Carlton, Boston Common.
Held in the heart of the Boston Biotech Hub, the invitation-only event will bring together C-Suite executives and influential leaders of the biopharmaceutical industry, academia, venture capital, and not-for-profit organizations to facilitate forward-thinking discussions and high-quality networking opportunities. Healthcare policy reform, the global economic crisis, and large pharmas’ imminent patent cliff have converged while unique opportunities in emerging markets and technological innovations appear with increasing frequency, leading to the pharmaceutical industry’s rapid transformation. Speakers will discuss strategies and redeployment of resources to leverage these high growth opportunities.
“Pharmaceutical sales in emerging markets are expected to grow at three times the rate of developed markets and account for 70 percent of the industry’s growth over the next several years,” said Janet Wolfe, Ph.D., President and Founder of WLI. “As US and European drug companies increasingly turn to emerging markets to stimulate growth, new challenges arise, many of which will be addressed with emerging technologies. We are absolutely thrilled to host the Wolfe Biopharma Conference, which will showcase industry leaders who will explore the future of the pharmaceutical industry.”
Opening remarks will be made by Robert Coughlin, President and CEO, MassBio and Janet Wolfe. Morning sessions focused on emerging markets will include:
- G. Steven Burrill, CEO
Burrill & Company
- Sam Azoulay, MD, SVP Medical & Development, Emerging Markets Business Unit
- Mervyn Turner, Ph.D., CSO and SVP, Emerging Markets Research & Development
Merck & Co.
- Melinda Moree, CEO
BIO Ventures for Global Health
- Howard Mayer, MD, CMO
Following lunch, afternoon sessions addressing emerging technologies will include:
- Robert Armstrong, Ph.D., VP, Global External Research & Development
Eli Lilly and Company
- Rick Panicucci, Ph.D., Global Head of Chemical and Pharmaceutical Profiling
Novartis Institutes for Biomedical Research
- Daniel Junius, President and CEO
- William Chin, MD, Executive Dean for Research
Harvard Medical School
- Ted Torphy, Ph.D., VP and Lead, External Innovation
Johnson & Johnson Pharmaceuticals
A personalized medicine panel moderated by Steven Dickman, CEO, CBT Advisors will include:
The Wolfe Biopharma Conference will conclude with a CEO plenary address panel focused on the importance of philanthropic initiatives within the Boston community. Wycliffe "Wyc" Grousbeck, Managing Partner, Governor, and CEO, The Boston Celtics and Doug Flutie, former starting quarterback, New England Patriots, and Founder, Doug Flutie Jr. Foundation for Autism will discuss their individual commitments to social responsibility and encourage others to give back to society.
With a strong commitment to providing science education to underprivileged youth, Wolfe Laboratories will donate net proceeds of the conference to the United Way of Massachusetts Bay and Merrimack Valley’sMath, Science, and Technology initiative, which provides after-school programs in science- and technology-related fields.
The Wolfe Biopharma Conference is sponsored by Datalink; Hitachi Data Systems.; Mintz Levin; and BioPharm Insight. To learn more about this event, click here. To request a private invitation, email@example.com.
About Wolfe Laboratories, Inc. (WLI)
WLI is a biopharmaceutical development company that offers customized translational research services and comprehensive IND-enabling programs for biologics and small molecules. Through its development services in the CMC and ADMET areas, as well as cGLP and cGMP testing, the company brings value to its clients by rapidly providing high quality project planning and execution through its experienced staff and management team. Drug Development Done Right. On Time. For more information, visit www.wolfelabs.com.
A complete data center solutions and services provider for Fortune 500 and mid-tier enterprises, Datalink transforms data centers so they become more efficient, manageable and responsive to changing business needs. Datalink helps leverage and protect storage, server, and network investments with a focus on long-term value, offering a full lifecycle of services, from consulting and design to implementation, management and support. Datalink solutions span virtualization and consolidation, data storage and protection, advanced networks, and business continuity. Each delivers measurable performance gains and maximizes the business value of IT. For more information, call 800.448.6314 or visit www.datalink.com.
About Hitachi Data Systems
Hitachi Data Systems provides best-in-class information technologies, services and solutions that deliver compelling customer ROI, unmatched return on assets (ROA) and demonstrable business impact. With a vision that IT must be virtualized, automated, cloud-ready and sustainable, Hitachi Data Systems offers solutions that improve IT costs and agility. With more than 4,200 employees worldwide, Hitachi Data Systems does business in more than 100 countries and regions. Hitachi Data Systems products, services and solutions are trusted by the world’s leading enterprises, including more than 70 percent of the Fortune 100 and more than 80 percent of the Fortune Global 100. Hitachi Data Systems believes that data drives our world – and information is the new currency. To learn more, visit www.hds.com.
About BioPharm Insight
BioPharm Insight is the leading provider of intelligence to the biotechnology & pharmaceutical industry. We provide: detailed company profiles for over 4,100 biotech & pharmaceutical companies; listings on 36,000+ investigational & 23,000+ approved drugs; contact info for 250,000+ industry contacts (includes email & direct phone); 3,000+, easy-to-digest, licensing agreement synopsis; product forecasts to 2018; and Pharmawire competitive intelligence. Our Pharmawire journalists cover the most important situations taking place in the life sciences industry. They tap leading CEOs, scientists, clinicians, lawyers, and other experts to provide forward looking insight into drug pipelines, upcoming litigation (including patent expirations), drug licensing deals, and mergers & acquisitions. Visit www.biopharminsight.com for more information.